Hepatocellular Carcinoma Clinical Trials in Philadelphia, Pennsylvania

6 studies are recruiting for hepatocellular carcinoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

   This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Philadelphia, Pennsylvania

   Locations

   219 in total

   Run by

   AstraZeneca

   See if you can join NCT06921785 on ClinicalTrials.gov

2. Y-90 Treatment Response Using Transarterial Radioembolization

   This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing c…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07145801 on ClinicalTrials.gov

3. Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

   This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapa…

   Stage

   Phase 1

   Ages

   20 to 99

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   2 in total

   Run by

   Teclison Ltd.

   See if you can join NCT02174549 on ClinicalTrials.gov

4. Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

   Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania

   Run by

   VA Office of Research and Development

   See if you can join NCT05842174 on ClinicalTrials.gov

5. Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

   The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combinat…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania

   Locations

   12 in total

   Run by

   Replimune, Inc.

   See if you can join NCT05733598 on ClinicalTrials.gov

6. SBRT With Atezo/Bev for HCC

   A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT05488522 on ClinicalTrials.gov